Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients

Aurelien Mary 1 Agnes Hartemann 2, 3, 4 Sophie Liabeuf 5, 1 Carole Elodie Aubert 6 Salim Kemel 7 Joe Elie Salem 8, 9, 10 Philippe Cluzel 11 Aurelie Lenglet 12 Ziad A. Massy 13, 14, 15 Jean-Daniel Lalau 12, 16, 1 Romuald Mentaverri 1 Olivier Bourron 4, 17, 9 Saïd Kamel 1 
Abstract : Background: Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. However, metformin's effects in patients with diabetic VC have not previously been characterized. The present study investigated the association between metformin use and lower-limb arterial calcification in patients with type 2 diabetes and high cardiovascular risk. Methods: The DIACART cross-sectional cohort study included 198 patients with type 2 diabetes but without severe chronic kidney disease. Below-the-knee calcification scores were assessed by computed tomography and supplemented by colour duplex ultrasonography. Data on anti-diabetic drugs were carefully collected from the patients' medical records and during patient interviews. Biochemical and clinical data were studied as potential confounding factors. Results: Metformin-treated patients had a significantly lower calcification score than metformin-free patients (mean +/- standard deviation: 2033 +/- 4514 and 4684 +/- 9291, respectively; p = 0.01). A univariate analysis showed that metformin was associated with a significantly lower prevalence of severe below-the-knee arterial calcification (p = 0.02). VC was not significantly associated with the use of other antidiabetic drugs, including sulfonylureas, insulin, gliptin, and glucagon like peptide-1 analogues. A multivariate logistic regression analysis indicated that the association between metformin use and calcification score (odds ratio [95% confidence interval] = 0.33 [0.11-0.98]; p = 0.045) was independent of age, gender, tobacco use, renal function, previous cardiovascular disease, diabetes duration, neuropathy, retinopathy, HbA(1c) levels, and inflammation. Conclusions: In patients with type 2 diabetes, metformin use was independently associated with a lower below-theknee arterial calcification score. This association may contribute to metformin's well-known vascular protective effect. Further prospective investigations of metformin's potential ability to inhibit VC in patients with and without type 2 diabetes are now needed to confirm these results.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : jeudi 3 février 2022 - 16:16:17
Dernière modification le : mercredi 28 septembre 2022 - 16:20:12

Lien texte intégral



Aurelien Mary, Agnes Hartemann, Sophie Liabeuf, Carole Elodie Aubert, Salim Kemel, et al.. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. Cardiovascular Diabetology, BioMed Central, 2017, 16, ⟨10.1186/s12933-017-0509-7⟩. ⟨hal-03555488⟩



Consultations de la notice